Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SHE:301126)
China · Delayed Price · Currency is CNY 10.21
-0.33 (-3.13%)
At close: May 29, 2026
SHE:301126 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,212 | 5,127 | 5,220 | 3,894 | 3,279 | 2,586 |
Other Revenue | 16.86 | 16.86 | 13.33 | 9.37 | 13.5 | 6.12 |
| 5,229 | 5,144 | 5,233 | 3,904 | 3,292 | 2,592 | |
Revenue Growth (YoY) | -0.46% | -1.70% | 34.07% | 18.56% | 27.01% | 10.79% |
Cost of Revenue | 4,283 | 4,212 | 4,197 | 3,335 | 2,901 | 2,292 |
Gross Profit | 945.83 | 932.12 | 1,036 | 568.05 | 391.68 | 300.35 |
Selling, General & Admin | 836.79 | 823.31 | 821.41 | 421.39 | 254.61 | 148.43 |
Research & Development | 11.64 | 11.85 | 16.26 | 7.17 | 0.52 | - |
Other Operating Expenses | -5.23 | -6.19 | -6.21 | 1.97 | 11.58 | 10.13 |
Operating Expenses | 864.77 | 848.97 | 839.34 | 445.44 | 283.46 | 172.06 |
Operating Income | 81.07 | 83.14 | 196.75 | 122.61 | 108.23 | 128.3 |
Interest Expense | -111.46 | -115.05 | -107.82 | -69.51 | -40.75 | -34.89 |
Interest & Investment Income | 3.38 | 3.31 | 3.54 | 5.3 | 7.74 | 1.05 |
Currency Exchange Gain (Loss) | -0 | -0 | - | - | - | - |
Other Non Operating Income (Expenses) | -15.3 | -15.45 | -6.36 | -9.25 | -4.74 | -2.68 |
EBT Excluding Unusual Items | -42.31 | -44.05 | 86.11 | 49.15 | 70.48 | 91.79 |
Impairment of Goodwill | -180.01 | -180.01 | -12.61 | - | - | - |
Gain (Loss) on Sale of Investments | 15.84 | 15.84 | -0.38 | -0.15 | - | - |
Gain (Loss) on Sale of Assets | 0.92 | 1.81 | 1.38 | 1.11 | 0.32 | - |
Asset Writedown | -16.01 | -16.36 | -0.06 | -0.48 | -0.01 | - |
Other Unusual Items | 1.75 | 2.35 | 1.55 | -1.07 | 5.39 | 4.22 |
Pretax Income | -219.83 | -220.43 | 76 | 48.55 | 76.17 | 96.01 |
Income Tax Expense | 9.31 | 8.32 | 24.66 | 10.54 | 20.85 | 27.75 |
Earnings From Continuing Operations | -229.14 | -228.75 | 51.33 | 38.01 | 55.32 | 68.26 |
Minority Interest in Earnings | -10.5 | -13.71 | -24.76 | -3.71 | -4.25 | - |
Net Income | -239.64 | -242.46 | 26.57 | 34.3 | 51.08 | 68.26 |
Net Income to Common | -239.64 | -242.46 | 26.57 | 34.3 | 51.08 | 68.26 |
Net Income Growth | - | - | -22.52% | -32.85% | -25.17% | 5.25% |
Shares Outstanding (Basic) | 216 | 205 | 204 | 202 | 204 | 155 |
Shares Outstanding (Diluted) | 216 | 205 | 204 | 202 | 204 | 155 |
Shares Change (YoY) | 13.78% | 0.51% | 1.32% | -1.25% | 31.70% | 0.47% |
EPS (Basic) | -1.11 | -1.18 | 0.13 | 0.17 | 0.25 | 0.44 |
EPS (Diluted) | -1.11 | -1.18 | 0.13 | 0.17 | 0.25 | 0.44 |
EPS Growth | - | - | -23.53% | -32.00% | -43.18% | 4.76% |
Free Cash Flow | -109.17 | -253.75 | -163.1 | -199.57 | -702.69 | -195.1 |
Free Cash Flow Per Share | -0.51 | -1.24 | -0.80 | -0.99 | -3.44 | -1.26 |
Dividend Per Share | 0.022 | 0.022 | 0.082 | 0.040 | 0.029 | 0.034 |
Dividend Growth | -73.11% | -73.11% | 104.50% | 37.93% | -14.71% | - |
Gross Margin | 18.09% | 18.12% | 19.80% | 14.55% | 11.90% | 11.59% |
Operating Margin | 1.55% | 1.62% | 3.76% | 3.14% | 3.29% | 4.95% |
Profit Margin | -4.58% | -4.71% | 0.51% | 0.88% | 1.55% | 2.63% |
Free Cash Flow Margin | -2.09% | -4.93% | -3.12% | -5.11% | -21.34% | -7.53% |
EBITDA | - | 144.3 | 247.57 | 206.05 | 130.85 | 142.38 |
EBITDA Margin | - | 2.80% | 4.73% | 5.28% | 3.98% | 5.49% |
D&A For EBITDA | - | 61.15 | 50.83 | 83.44 | 22.63 | 14.08 |
EBIT | 81.07 | 83.14 | 196.75 | 122.61 | 108.23 | 128.3 |
EBIT Margin | 1.55% | 1.62% | 3.76% | 3.14% | 3.29% | 4.95% |
Effective Tax Rate | - | - | 32.46% | 21.72% | 27.37% | 28.90% |
Revenue as Reported | 5,229 | 5,144 | 5,233 | 3,904 | 3,292 | 2,592 |
Advertising Expenses | - | 79.56 | 77.9 | 34.34 | 8.87 | - |